CRISPR Therapeutics AG has announced a significant collaboration with Sirius Therapeutics, involving a Collaboration, Option and License Agreement. This partnership aims to advance the research, development, manufacture, and commercialization of innovative siRNA technology targeting Factor XI. A key focus of this collaboration is the co-development and commercialization of SRSD107, a next-generation siRNA designed to inhibit human coagulation factor XI, which is implicated in pathological thrombosis. This collaboration aims to reduce thrombotic events with minimal bleeding risk. The agreement includes options for CRISPR Therapeutics to exclusively license Sirius' siRNA technology for up to two additional targets, with potential milestone payments totaling $87.5 million. Both companies have committed to exclusivity in this field, prohibiting any siRNA-based advances targeting factor XI outside of this partnership.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.